These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 7740053)

  • 21. Dopamine D1 and D2 receptor ligands modulate the behaviour of mice in the elevated plus-maze.
    Rodgers RJ; Nikulina EM; Cole JC
    Pharmacol Biochem Behav; 1994 Dec; 49(4):985-95. PubMed ID: 7886117
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dopamine mediates striatal malonate toxicity via dopamine transporter-dependent generation of reactive oxygen species and D2 but not D1 receptor activation.
    Xia XG; Schmidt N; Teismann P; Ferger B; Schulz JB
    J Neurochem; 2001 Oct; 79(1):63-70. PubMed ID: 11595758
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The effect of intrastriatal application of directly and indirectly acting dopamine agonists and antagonists on the in vivo release of acetylcholine measured by brain microdialysis. The importance of the post-surgery interval.
    De Boer P; Damsma G; Schram Q; Stoof JC; Zaagsma J; Westerink BH
    Naunyn Schmiedebergs Arch Pharmacol; 1992 Feb; 345(2):144-52. PubMed ID: 1349159
    [TBL] [Abstract][Full Text] [Related]  

  • 24. D-cycloserine decreases both D1 and D2 dopamine receptors number and their function in rat brain.
    Gandolfi O; Rimondini R; Dall'Olio R
    Pharmacol Biochem Behav; 1994 Jun; 48(2):351-6. PubMed ID: 7916464
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dopamine D(1) receptor-mediated control of striatal acetylcholine release by endogenous dopamine.
    Acquas E; Di Chiara G
    Eur J Pharmacol; 1999 Oct; 383(2):121-7. PubMed ID: 10585525
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Fetal behavior and the dopamine system: activity effects of D1 and D2 receptor manipulations.
    Moody CA; Robinson SR; Spear LP; Smotherman WP
    Pharmacol Biochem Behav; 1993 Apr; 44(4):843-50. PubMed ID: 8097042
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Loss of D1/D2 dopamine receptor synergisms following repeated administration of D1 or D2 receptor selective antagonists: electrophysiological and behavioral studies.
    Hu XT; White FJ
    Synapse; 1994 May; 17(1):43-61. PubMed ID: 7913772
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Central dopamine D
    Ikeda H; Yonemochi N; Mikami R; Abe M; Kawamura M; Natsume R; Sakimura K; Waddington JL; Kamei J
    Sci Rep; 2020 Dec; 10(1):22347. PubMed ID: 33339892
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pressure reversed extracellular striatal dopamine decrease produced by D1 receptor agonist SKF 38393, and D2 receptor agonist LY 171555, but failed to change the effect of the activation of both D1 and D2 receptors.
    Abraini JH; Fechtali T; Rostain JC
    Neuroscience; 1992 Sep; 50(2):395-402. PubMed ID: 1359460
    [TBL] [Abstract][Full Text] [Related]  

  • 30. D1-D2 dopamine receptor synergy in striatum: effects of intrastriatal infusions of dopamine agonists and antagonists on immediate early gene expression.
    Keefe KA; Gerfen CR
    Neuroscience; 1995 Jun; 66(4):903-13. PubMed ID: 7651617
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The D1 agonist SKF 38393 increases dopamine release in the developing rat striatum.
    Walters DE; Howard SG
    Eur J Pharmacol; 1990 Aug; 184(2-3):257-64. PubMed ID: 2150376
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dopamine D1- and D2-receptor interaction in turning behaviour induced by dopamine agonists in 6-hydroxydopamine-lesioned rats.
    Karlsson G; Jaton AL; Vigouret JM
    Neurosci Lett; 1988 May; 88(1):69-74. PubMed ID: 2969468
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Regulation of prefrontal cortical dopamine release by dopamine receptor agonists and antagonists.
    Santiago M; Machado A; Cano J
    Eur J Pharmacol; 1993 Aug; 239(1-3):83-91. PubMed ID: 7901031
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Enhanced response to the inhibitory action of LY171555, a dopamine D2-agonist, on in vivo striatal dopamine release in DOCA/NaCl-hypertensive rats.
    Chen YF; Oparil S
    Brain Res; 1987 Jan; 400(2):225-31. PubMed ID: 2949797
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ventral hippocampal dopamine D1 and D2 systems and spatial working memory in rats.
    Wilkerson A; Levin ED
    Neuroscience; 1999 Mar; 89(3):743-9. PubMed ID: 10199609
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Reserpine increases Fos activity in the rat basal ganglia via a quinpirole-sensitive mechanism.
    Cole DG; Di Figlia M
    Neuroscience; 1994 May; 60(1):115-23. PubMed ID: 7914358
    [TBL] [Abstract][Full Text] [Related]  

  • 37. DTG-induced circling behaviour in rats may involve the interaction between sigma sites and nigro-striatal dopaminergic pathways.
    Bastianetto S; Rouquier L; Perrault G; Sanger DJ
    Neuropharmacology; 1995 Mar; 34(3):281-7. PubMed ID: 7630482
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In vivo release of [3H]gamma-aminobutyric acid in the rat neostriatum--II. Opposing effects of D1 and D2 dopamine receptor stimulation in the dorsal caudate putamen.
    Girault JA; Spampinato U; Glowinski J; Besson MJ
    Neuroscience; 1986 Dec; 19(4):1109-17. PubMed ID: 2950336
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mediation of dopamine D1 and D2 receptors in the effects of GBR 12909 on latent learning and locomotor activity in mice.
    Ichihara K; Nabeshima T; Kameyama T
    Eur J Pharmacol; 1993 Apr; 234(2-3):155-63. PubMed ID: 8097720
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Chronic CY 208-243 treatment of MPTP-monkeys causes regional changes of dopamine and GABAA receptors.
    Gagnon C; Gomez-Mancilla B; Bédard PJ; Di Paolo T
    Neurosci Lett; 1993 Nov; 163(1):31-5. PubMed ID: 7905197
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.